SCHEMBL165682

SCHEMBL165682

Cc1cc(Nc2nc(C(F)(F)c3ccc(F)cc3)nc3cc(C4(O)COC4)ccc23)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.46
AURKB Q96GD4 5/20 0.46
NTRK1 P04629 8/20 0.46
NTRK3 Q16288 3/20 0.46
NTRK2 Q16620 3/20 0.46
JAK2 O60674 3/20 0.42
CYP3A4 P08684 3/20 0.42
CYP2C8 P10632 3/20 0.42
CYP2C9 P11712 3/20 0.42
JAK1 P23458 3/20 0.42
TYK2 P29597 3/20 0.42
CYP2C19 P33261 3/20 0.42
JAK3 P52333 3/20 0.42
ADORA3 P0DMS8 2/20 0.42
CYP1A2 P05177 1/20 0.42
PLK4 O00444 1/20 0.39
PAK4 O96013 1/20 0.39
GSK3B P49841 2/20 0.39
SRC P12931 1/20 0.39
EIF2AK2 P19525 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL175070 0.84 AURKA (0.63) AURKAAURKBNTRK1NTRK3NTRK2
SCHEMBL174009 0.82 NTRK1 (0.56) AURKAAURKBNTRK1NTRK3NTRK2
SCHEMBL173978 0.80 NTRK1 (0.54) AURKAAURKBNTRK1NTRK3NTRK2
SCHEMBL168759 0.79 NTRK1 (0.66) AURKAAURKBNTRK1NTRK3NTRK2
SCHEMBL173976 0.79 AURKA (0.62) AURKAAURKBNTRK1NTRK3NTRK2
SCHEMBL175276 0.78 AURKA (0.51) AURKAAURKBNTRK1NTRK3NTRK2
SCHEMBL168727 0.77 AURKA (0.47) AURKAAURKBNTRK1NTRK3NTRK2
SCHEMBL168181 0.77 TYK2 (0.48) AURKAAURKBNTRK1NTRK3NTRK2
SCHEMBL165121 0.77 ACSS2 (0.33)
SCHEMBL165107 0.77 AURKA (0.52) AURKAAURKBNTRK1NTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130225578-A1 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-08-29 US claimed
EP-2611448-A1 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 EP claimed
WO-2012030912-A1 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO claimed
US-20130225578-A1 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-08-29 US disclosed
US-20130225578-A1 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-08-29 US disclosed
US-20130225578-A1 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-08-29 US disclosed
EP-2611448-A1 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 EP disclosed
WO-2012030912-A1 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225578-A1 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF JAK2, JAK3, TYK2 AURKA 480/4885AURKB 336/4885NTRK1 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.